Wedbush Predicts Weaker Earnings for TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at Wedbush decreased their FY2025 earnings per share estimates for TScan Therapeutics in a note issued to investors on Wednesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($1.07) for the year, down from their prior forecast of ($1.03). Wedbush has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.70) EPS, FY2027 earnings at ($0.74) EPS and FY2028 earnings at ($0.64) EPS.

Several other research firms also recently commented on TCRX. HC Wainwright decreased their price target on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. BTIG Research lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Needham & Company LLC lowered their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.60.

TScan Therapeutics Stock Up 2.1%

Shares of TCRX opened at $0.99 on Monday. The firm has a market cap of $56.19 million, a P/E ratio of -0.88 and a beta of 1.00. The stock has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $1.69. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. TScan Therapeutics has a 1 year low of $0.96 and a 1 year high of $4.94.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $1.98 million. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. BVF Inc. IL grew its holdings in TScan Therapeutics by 6.9% in the 2nd quarter. BVF Inc. IL now owns 5,226,074 shares of the company’s stock worth $7,578,000 after acquiring an additional 336,600 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of TScan Therapeutics by 7.8% during the third quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock worth $4,219,000 after purchasing an additional 168,540 shares during the period. Checkpoint Capital L.P. boosted its holdings in shares of TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock worth $2,784,000 after purchasing an additional 261,663 shares during the period. Aberdeen Group plc grew its stake in shares of TScan Therapeutics by 52.0% in the third quarter. Aberdeen Group plc now owns 1,354,820 shares of the company’s stock worth $2,466,000 after purchasing an additional 463,372 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in TScan Therapeutics by 14.9% during the 3rd quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock valued at $763,000 after purchasing an additional 54,370 shares during the period. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.